1220039-64-4

Basic information

• Product Name: 4-BroMopyridazine HydrobroMide
• Synonyms: 4-BroMopyridazine HydrobroMide
• CAS NO: 1220039-64-4
• Molecular Formula: BrH*C₄H₃BrN₂
• Molecular Weight: 239.89596
• Product Categories: Aromatics;Heterocycles;Intermediates
• Mol File: 1220039-64-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightky)
• Stability: Shock sensitive, temperature sensitive, light sensitive
• CAS DataBase Reference: 4-BroMopyridazine HydrobroMide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMopyridazine HydrobroMide(1220039-64-4)
• EPA Substance Registry System: 4-BroMopyridazine HydrobroMide(1220039-64-4)

Safety Data

• Hazardous Substances Data: 1220039-64-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-pyridazine hydrobromide is used as a key intermediate compound for the synthesis of γ-secretase modulators. These modulators play a crucial role in the treatment of various neurodegenerative diseases, such as Alzheimer's, by regulating the production of amyloid-beta peptides, which are implicated in the pathology of these conditions.

Upstream product

• 22037-28-1 3-bromofurane 

Downstream Products

• 1231191-50-6 6-fluoro-3-[4-(4-pyridazin-4-ylphenyl)-1H-1,2,3-triazol-1-yl]-1-(2,2,2-trifluoroethyl)-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 
• 1332519-16-0 methyl 2-methoxy-4-methyl-5-(pyridazin-4-yl)benzoate 
• 1354917-78-4 4-[2-chloro-5-(trifluoromethyl)phenyl]pyridazine 
• 1616069-42-1 4-(3-iodo-1H-pyrazol-1-yl)pyridazine 
• 1354786-58-5 4-chloro-2-pyridazin-4-ylphenol 
• 1354786-57-4 4-(5-chloro-2-methoxyphenyl)pyridazine 

Relevant articles and documents

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula (I) wherein: R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

CHEMICAL COMPOUNDS

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7

Chemical Compounds

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z1, Ra, Rb, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.